The Society for Immunotherapy of Cancer (SITC) hosted Session 207b during the 39th Annual Meeting & Pre-Conference Programs on Saturday, November 9, 2024. Available here are the presentation slides and video from “Session 207b: Everything but the Cell: Priming Patients for T Cell Administration” as permitted by presenters.
Stephanie Goff, MD, FACS – National Cancer Institute
Marco Ruella, MD – University of Pennsylvania
This session delves into the critical role of lymphodepletion as a preparatory step in adoptive T-cell therapies. The speakers will explore the foundations, current practices, and future directions of lymphodepletion strategies to optimize the efficacy of T-cell administration in cancer treatment. Dr. Goff will provide an insightful overview of lymphodepletion, sharing her extensive experience with tumor-infiltrating lymphocytes (TILs) and early CAR-T. This talk will highlight key clinical outcomes and lessons learned from pioneering treatments at the National Cancer Institute. Dr. Ruella will discuss the specific applications of lymphodepletion in CAR-T and TCR-engineered T-cell therapies. His presentation will cover the practical aspects of patient preparation, focusing on optimizing treatment efficacy and patient safety. Dr. Paulos will delve into the mechanistic insights and the importance of preclinical models in understanding lymphodepletion. Her talk aims to bridge the gap between laboratory findings and clinical applications, providing a robust scientific foundation. Lastly, the panel discussion will explore emerging strategies and innovations designed to enhance the safety and effectiveness of lymphodepletion. The session will examine potential advancements that could revolutionize how patients are prepared for adoptive T-cell therapies. Attendees will gain a comprehensive understanding of the various facets of lymphodepletion, including current techniques, challenges, and innovative approaches on the horizon. This session is designed for clinicians, researchers, and healthcare professionals involved in the field of cancer immunotherapy, offering critical insights that could shape future treatment protocols.
To view the entire program schedule (including presenter permission to post) please click here.
01:24:22